Cargando…

Laquinimod dampens IL-1β signaling and Th17-polarizing capacity of monocytes in patients with MS

OBJECTIVE: To assess the impact of laquinimod treatment on monocytes and to investigate the underlying immunomodulatory mechanisms in MS. METHODS: In this cross-sectional study, we performed in vivo and in vitro analyses of cluster of differentiation (CD14(+)) monocytes isolated from healthy donors...

Descripción completa

Detalles Bibliográficos
Autores principales:	Engel, Sinah, Jolivel, Valérie, Kraus, Stefan H.-P., Zayoud, Morad, Rosenfeld, Karolina, Tumani, Hayrettin, Furlan, Roberto, Kurschus, Florian C., Waisman, Ari, Luessi, Felix
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7676421/ https://www.ncbi.nlm.nih.gov/pubmed/33203651 http://dx.doi.org/10.1212/NXI.0000000000000908

Ejemplares similares

Laquinimod dampens hyperactive cytokine production in Huntington's disease patient myeloid cells
por: Dobson, Lucianne, et al.
Publicado: (2016)

Laquinimod Modulates Human Astrocyte Function and Dampens Astrocyte-Induced Neurotoxicity during Inflammation
por: Colombo, Emanuela, et al.
Publicado: (2020)

Safety and in vivo immune assessment of escalating doses of oral laquinimod in patients with RRMS
por: Ziemssen, Tjalf, et al.
Publicado: (2017)

GFAPα IgG-associated encephalitis upon daclizumab treatment of MS
por: Luessi, Felix, et al.
Publicado: (2018)

Association of intrathecal pleocytosis and IgG synthesis with axonal damage in early MS
por: Engel, Sinah, et al.
Publicado: (2020)

Regulation of IL-22BP in psoriasis
por: Voglis, Stefanos, et al.
Publicado: (2018)

Intrathecal B-cell accumulation and axonal damage distinguish MRI-based benign from aggressive onset in MS
por: Engel, Sinah, et al.
Publicado: (2019)

Laquinimod Inhibits Inflammation-Induced Angiogenesis in the Cornea
por: Li, Zuohong, et al.
Publicado: (2020)

Laquinimod Supports Remyelination in Non-Supportive Environments
por: Nyamoya, Stella, et al.
Publicado: (2019)

Laquinimod Therapy in Multiple Sclerosis: A Comprehensive Review
por: Kolb-Sobieraj, Channa, et al.
Publicado: (2014)

A phase II study of laquinimod in Crohn's disease
por: D'Haens, Geert, et al.
Publicado: (2015)

Laquinimod treatment in the R6/2 mouse model
por: Ellrichmann, Gisa, et al.
Publicado: (2017)

A Case of Progressive Multifocal Leukoencephalopathy in a Fumaric Acid-Treated Psoriasis Patient With Severe Lymphopenia Among Other Risk Factors
por: Engel, Sinah, et al.
Publicado: (2021)

Laquinimod reduces neuroaxonal injury through inhibiting microglial activation
por: Mishra, Manoj Kumar, et al.
Publicado: (2014)

Laquinimod ameliorates excitotoxic damage by regulating glutamate re-uptake
por: Gentile, Antonietta, et al.
Publicado: (2018)

The TRACK-MS Test Battery: A Very Brief Tool to Track Multiple Sclerosis-Related Cognitive Impairment
por: Taranu, Daniela, et al.
Publicado: (2022)

Is APOE ε4 associated with cognitive performance in early MS?
por: Engel, Sinah, et al.
Publicado: (2020)

Laquinimod Protects Against TNF-α-Induced Attachment of Monocytes to Human Aortic Endothelial Cells (HAECs) by Increasing the Expression of KLF2
por: Jiang, Tiechao, et al.
Publicado: (2020)

PPMS onset upon adalimumab treatment extends the spectrum of anti-TNF-α therapy-associated demyelinating disorders
por: Engel, Sinah, et al.
Publicado: (2020)

Laquinimod in the treatment of multiple sclerosis: a review of the data so far
por: Thöne, Jan, et al.
Publicado: (2016)

Laquinimod protects the optic nerve and retina in an experimental autoimmune encephalomyelitis model
por: Wilmes, Anna T., et al.
Publicado: (2018)

Author Correction: Laquinimod treatment in the R6/2 mouse model
por: Ellrichmann, Gisa, et al.
Publicado: (2019)

Ocrelizumab-induced vulvovaginal pyoderma gangrenosum in a patient with relapsing-remitting multiple sclerosis
por: Klumpp, Annika, et al.
Publicado: (2022)

Laquinimod prevents cuprizone-induced demyelination independent of Toll-like receptor signaling
por: Kramann, Nadine, et al.
Publicado: (2016)

Targeting “bad” B cells in multiple sclerosis: Could laquinimod be part of the armamentarium?
por: Forsthuber, Thomas G., et al.
Publicado: (2016)

Aryl Hydrocarbon Receptor Activation in Astrocytes by Laquinimod Ameliorates Autoimmune Inflammation in the CNS
por: Rothhammer, Veit, et al.
Publicado: (2021)

Elevated neurofilament light chain CSF/serum ratio indicates impaired CSF outflow in idiopathic intracranial hypertension
por: Engel, Sinah, et al.
Publicado: (2023)

Treatment of spontaneous EAE by laquinimod reduces Tfh, B cell aggregates, and disease progression
por: Varrin-Doyer, Michel, et al.
Publicado: (2016)

Laquinimod efficacy in relapsing-remitting multiple sclerosis: how to understand why and if studies disagree
por: Cutter, Gary R., et al.
Publicado: (2016)

Laquinimod attenuates inflammation by modulating macrophage functions in traumatic brain injury mouse model
por: Katsumoto, Atsuko, et al.
Publicado: (2018)

Neurochemical Biomarkers in patients with COVID-19
por: Tumani, Hayrettin
Publicado: (2023)

A Score Based on NfL and Glial Markers May Differentiate Between Relapsing–Remitting and Progressive MS Course
por: Huss, André, et al.
Publicado: (2020)

Implications of extreme serum neurofilament light chain levels for the management of patients with relapsing multiple sclerosis
por: Engel, Sinah, et al.
Publicado: (2021)

Reduced astrocytic NF-κB activation by laquinimod protects from cuprizone-induced demyelination
por: Brück, Wolfgang, et al.
Publicado: (2012)

Transcriptomic Impact of IMA-08401, a Novel AHR Agonist Resembling Laquinimod, on Rat Liver
por: Prokopec, Stephenie D., et al.
Publicado: (2019)

To dampen demyelination
por: Maxmen, Amy
Publicado: (2010)

Environmental signals perceived by the brain abate pro-metastatic monocytes by dampening glucocorticoids receptor signaling
por: Canali, María Magdalena, et al.
Publicado: (2023)

A PET-CT study on neuroinflammation in Huntington’s disease patients participating in a randomized trial with laquinimod
por: Roussakis, Andreas-Antonios, et al.
Publicado: (2023)

Association of serum neurofilament light chain levels and neuropsychiatric manifestations in systemic lupus erythematosus
por: Engel, Sinah, et al.
Publicado: (2021)

Chemical dampening of Ly6C(hi) monocytes in the periphery produces anti-depressant effects in mice
por: Zheng, Xiao, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_55nrju15s32rfkshbp0o37l10a